Clinical trials: Stage I Ovarian Cancer
Ovarian Cancer, Breast Cancer
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid…
- Conditions
- Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
- Trial name
- PETRA (NCT04644068)
- Testing
- AZD5305, Paclitaxel, Carboplatin
- Where
- 68 sites in United States, Australia and 12 more
- Volunteers
- 702 people
- Sponsor
- AstraZeneca
Advanced Cancer, Metastatic Cancer
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: Find the recommended dose of ART0380 that can be given safely to participants…
- Conditions
- Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04657068
- Testing
- ART0380, Gemcitabine, Irinotecan
- Where
- 88 sites in United States, France and 2 more
- Volunteers
- 542 people
- Sponsor
- Artios Pharma Ltd
Ovarian Cancer
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
This study, will take a subject's "T cells" and "teach" them to be able to recognize and attack the ovarian cancer cells. This is done by putting in a gene or genetic material that will change how a subject's T cells work and…
- Trial name
- NCT01567891
- Testing
- NYESO-1c259 T cells
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Adaptimmune
Tumor
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves…
- Trial name
- NCT00413322
- Testing
- belinostat, 5-Fluorouracil (5-FU)
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Valerio Therapeutics
Ovarian Cancer
Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)
This clinical trial shall clarify the efficacy and safety of pazopanib in combination with weekly topotecan in patients with platinum-resistant or intermediate platinum-sensitive recurrent epithelial ovarian cancer, fallopian and…
- Trial name
- NCT01600573
- Testing
- pazopanib in combination with weekly topotecan
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- JSehouli
Breast Cancer
Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00002580
- Testing
- cyclophosphamide, fluorouracil, goserelin acetate
- Where
- 10 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Scottish Cancer Therapy Network
Platinum Resistant Ovarian Cancer, Fallopian Tube Cancers
Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
This is an open-label, Phase 1 clinical study to evaluate the safety, tolerability, PK profiles, and clinical activity of IV and PO arginine supplementation + SOC chemoimmunotherapy regimens in participants with PROC.
- Conditions
- Platinum Resistant Ovarian Cancer, Fallopian Tube Cancers, Peritoneal Carcinoma
- Trial name
- NCT07772882
- Testing
- (Arginaid®) Oral Arginine, (R-Gene® 10) IV Arginine, Pembrolizumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Rebecca Arend
Breast Cancer
Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00002582
- Testing
- CMF regimen, cyclophosphamide, doxorubicin hydrochloride
- Where
- 2 sites in United Kingdom
- Volunteers
- 6,000 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor
Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy, such as cisplatin, ifosfamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma
- Trial name
- NCT00470366
- Testing
- pegfilgrastim, cisplatin, ifosfamide
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasms
Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
The purpose of the study is to determine if the maximum tolerated doses of AZD2171, in combination with AZD0530, in treating patients with advanced solid tumours are safe, tolerable and efficacious.
- Trial name
- NCT00475956
- Testing
- AZD2171, AZD0530
- Where
- 3 sites in Germany
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Ovarian Neoplasms, Ovarian Epithelial Carcinoma
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
The study aims to develop a test for early detection of ovarian cancer using DNA from a growth involving the ovary found in a washing of the uterus (womb), and proteins found in the blood.
- Conditions
- Ovarian Neoplasms, Ovarian Epithelial Carcinoma, Fallopian Tube Neoplasms, High Grade Ovarian Serous Adenocarcinoma
- Trial name
- NCT04794322
- Testing
- Uterine lavage, or a wash of the womb, Blood sample, Pap smear
- Where
- 6 sites in United States
- Volunteers
- 250 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer, Ovarian Cancer
A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
The goal of this clinical trial is to learn if the investigational drug BL0175 works to treat adult postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative locally advanced…
- Conditions
- Breast Cancer, Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT06738966
- Testing
- BL0175
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- Shanghai Best-Link Bioscience, LLC
Stage I Ovarian Cancer AJCC v6 and v7, Stage IA Fallopian Tube Cancer AJCC v6 and v7
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
This trial studies the chemotherapy toxicity on quality of life in older patients with stage I, stage II, stage III, or stage IV ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer.
- Conditions
- Stage I Ovarian Cancer AJCC v6 and v7, Stage IA Fallopian Tube Cancer AJCC v6 and v7, Stage IB Fallopian Tube Cancer AJCC v6 and v7, Stage IC Fallopian Tube Cancer AJCC v6 and v7
- Trial name
- NCT01366183
- Testing
- Assessment of Therapy Complications, Carboplatin, Filgrastim
- Where
- 357 sites in United States
- Volunteers
- 290 people
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Peritoneal Cancer
Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer
This trial is a Phase I open-label safety study of Prolanta™, a recombinant analog of the human prolactin protein with a single amino acid substitution to create an antagonist of the prolactin receptor.
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- ProlantaOC (NCT02534922)
- Testing
- Prolanta, a human prolactin receptor antagonist
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Oncolix, Inc.
Pancreatic Adenocarcinoma, Ovarian Cancer
Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer
This Phase I/II trial evaluates LOAd703 in patients with cancer (pancreatic, biliary, colorectal or ovarian) together with their standard of care chemotherapy or using gemcitabine immune-conditioning.
- Conditions
- Pancreatic Adenocarcinoma, Ovarian Cancer, Biliary Carcinoma, Colorectal Cancer
- Trial name
- NCT03225989
- Testing
- LOAd703
- Where
- 2 sites in Sweden
- Volunteers
- 47 people
- Sponsor
- Lokon Pharma AB
Renal Cell Carcinoma, Ovarian Tumor
A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
This clinical trial will evaluate raludotatug deruxtecan (R-DXd; DS-6000a) in participants with advanced renal cell carcinoma (RCC) and ovarian cancer (OVC).
- Trial name
- NCT04707248
- Testing
- DS-6000a
- Where
- 13 sites in United States, Japan
- Volunteers
- 179 people
- Sponsor
- Daiichi Sankyo
Advanced Solid Tumors, Glioblastoma
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
Prospective, open-label, dose-ranging, uncontrolled phase I/II study of Lurbinectedin in combination with irinotecan. The study will be divided into two stages: a Phase I dose escalation stage and a Phase II expansion stage.
- Conditions
- Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST), Endometrial Carcinoma
- Trial name
- NCT02611024
- Testing
- Lurbinectedin, Irinotecan
- Where
- 23 sites in United States, France and 4 more
- Volunteers
- 316 people
- Sponsor
- PharmaMar
Ovarian Cancer, Melanoma
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination with Pembrolizumab in Subjects with Locally Advanced/Metastatic Solid…
- Conditions
- Ovarian Cancer, Melanoma, Triple Negative Breast Cancer, Colorectal Cancer
- Trial name
- NCT05746897
- Testing
- NM1F Injection, Pembrolizumab injection
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Hefei TG ImmunoPharma Co., Ltd.
Ovarian Cancer
Docetaxel and Oxaliplatin in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00075543
- Testing
- docetaxel, oxaliplatin
- Where
- 5 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Advanced High-grade Ovarian Cancer, Triple Negative Breast Cancer
Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors
This study is designed to evaluate the safety, tolerability, PKharmacokinetic profile and treatment effect of pamiparib in Chinese participants with advanced high-grade ovarian cancer (including fallopian cancer or primary…
- Trial name
- NCT03333915
- Testing
- Pamiparib
- Where
- 6 sites in China
- Volunteers
- 128 people
- Sponsor
- BeiGene